sellWeak cluster of 310b5-1 plan
Andrew Cheng sold $2.9M of AKRO
President and CEO at Akero Therapeutics, Inc.. 91,634 shares at an average of $31.41, traded Oct 16, 2024, filed Oct 18, 2024.
Warning score
35Value
$2.9M
91,634 shares
Holdings after
605,417
-15% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$2.9M at market
- +5Share of holdings soldSold 15% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-115731, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 16, 2024 | MOption exercise Common Stock10b5-1 | +24,992 | $21.10 | $527k | 630,409 | Oct 18, 2024 |
| Oct 16, 2024 | SOpen-market sale Common Stock10b5-1 | -24,992 | $31.14 | $778k | 605,417 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Common Stock10b5-1 | +3,103 | $21.10 | $65k | 608,520 | Oct 18, 2024 |
| Oct 17, 2024 | SOpen-market sale Common Stock10b5-1 | -3,103 | $31.12 | $97k | 605,417 | Oct 18, 2024 |
| Oct 18, 2024 | MOption exercise Common Stock10b5-1 | +63,539 | $21.10 | $1.3M | 668,956 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stock10b5-1 | -63,313 | $31.53 | $2.0M | 605,643 | Oct 18, 2024 |
| Oct 18, 2024 | SOpen-market sale Common Stock10b5-1 | -226 | $32.12 | $7,259 | 605,417 | Oct 18, 2024 |
| Oct 16, 2024 | MOption exercise Stock Option (Righto Buy)derivative10b5-1 | -24,992 | $0.00 | $0 | 160,351 | Oct 18, 2024 |
| Oct 17, 2024 | MOption exercise Stock Option (Righto Buy)derivative10b5-1 | -3,103 | $0.00 | $0 | 157,248 | Oct 18, 2024 |
| Oct 18, 2024 | MOption exercise Stock Option (Righto Buy)derivative10b5-1 | -63,539 | $0.00 | $0 | 93,709 | Oct 18, 2024 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.6M 30,000 shares | -5% | |
| 14Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $576k 12,500 shares | -7% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $597k 12,500 shares | -6% | |
| 30Weak | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.4M 31,796 shares | -6% | |
| 30Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $24k 553 shares | -0% | |
| 42Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $28k 659 shares | -1% | |
| 35Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $28k 659 shares | -1% | |
| 40Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $25k 586 shares | -0% | |
| 14Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $552k 12,500 shares | -7% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $576k 12,500 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.